Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 - Deals and Agreements Entered into by the Worlds Leading Life Science Companies

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. Fully up to date, the report provides details of joint venture agreements from 2010.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. Fully up to date, the report provides details of joint venture agreements from 2010.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

Key benefits:

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in joint venture partnerships

3. Overview of joint venture deal structure

4. Leading joint venture deals

5. Top 50 most active active joint venture dealmakers

6. Joint venture deals including contracts directory

For more information about this report visit https://www.researchandmarkets.com/research/npdbwn/global_joint

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716